WuXi Biologics (Cayman) stock

2269 · HKEX · HKD

$46.74Change from previous close: 0.00%

Close · November 16, 2026

Price history

+44.44% over the period

1 year: from $32.36 (November 17, 2025) to $46.74 (November 16, 2026), +44.44%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$46.74
October 30, 2026$44.48
September 30, 2026$56.05
August 31, 2026$48.84
July 31, 2026$38.74
June 30, 2026$34.60
May 29, 2026$33.34
April 30, 2026$33.04
March 31, 2026$33.02
February 27, 2026$40.22
January 30, 2026$37.00
December 31, 2025$31.44
November 28, 2025$31.16
November 17, 2025$32.36

At a glance

  • The company

    Provides end-to-end biologics discovery, development, and manufacturing services through contract research and manufacturing platforms

  • Latest results

    Quarter to June 30, 2026 · EPS ¥0.58

TickerLandia's take on WuXi Biologics (Cayman)

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$28.48
52-wk high$58.00

−19.41% from the 52-week high

Analysts · 27 analysts

Average target$60.21+28.82% vs. price

Buy 23 · Hold 4 · Sell 0 · Strong buy

TickerLandia Fingerprint: WuXi Biologics (Cayman)

Compared with similar companies: very high earnings stability and very strong momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

WuXi Biologics (Cayman) is cheaper than similar companies

WuXi Biologics (Cayman)'s P/E (trailing 12 months): 35.1, −13% against the median of a group of 8 similar companies (40.2).

Compared with 8 similar companies

WuXi Biologics (Cayman)'s metrics compared with similar companies
MetricWuXi Biologics (Cayman)Position in the groupBand
P/E (trailing 12 months)35.1Middle
Forward P/E21.4Low
Operating margin32.4%High
ROE11.4%Middle
Debt/equity0.05Low

Grey band: the middle half of the group; tick: the median; dot: WuXi Biologics (Cayman). All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥11.79B

Latest quarter · Q2 2026

Net income

¥2.44B

Latest quarter · Q2 2026

Quarterly net margin

20.7%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$192.4B
P/E
35.1
EPS
$1.33
Volume
28.51M
Daily trading
€177.87M
Dividend yield
0.00%

How WuXi Biologics (Cayman) is changing

All results
  • Revenue grew 31.2% a year on average over the last 5 years

  • Operating margin rose from 28.5% to 30.5%

  • Less cash than profit: free cash flow equal to 39% of net income

Returns

WuXi Biologics (Cayman) returns

$1,000 invested in WuXi Biologics (Cayman) 5 years ago, on November 16, 2021, would be worth $424 today: −57.59% in total, −15.77% per year. This is the price return only: dividends are excluded.

PeriodWuXi Biologics (Cayman)Hang Seng$1,000 becomes
1 month−3.03%−1.79%$970
6 months+38.78%−8.96%$1,388
Year to date+48.66%−7.32%$1,487
1 year+44.44%−9.97%$1,444
3 years−2.12%+33.20%$979
5 years−57.59%−7.62%$424

Over the last 6 months it has done better than 90% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

WuXi Biologics (Cayman): technical analysis

WuXi Biologics (Cayman) shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 67.9% below its all-time closing high ($145.60, June 28, 2021).

Trend
No clear trend
RSI (14 sessions)
45
Between 30 and 70
vs 200-session average
+15.65%

Support and resistance

Price areas where WuXi Biologics (Cayman) has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$48.30+3.34%2 touches, last on August 31, 2026
  2. Last price$46.74
  3. Support$43.24−7.49%3 touches, last on November 3, 2026
  4. Support$40.60−13.14%3 touches, last on July 16, 2026
  5. Support$36.91−21.02%3 touches, last on July 30, 2026

Volatility and risk

Over the last year it has moved more than the Hang Seng.

Beta (1 year) vs Hang Seng
1.26
Volatility (60 sessions, annualised)
50.8%
Largest fall in the last year
−28.74%

Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

WuXi Biologics (Cayman): seasonality

Average monthly price change over 10 years

+5.3%Jan+0.7%Feb−0.2%Mar−0.0%Apr+0.2%May+6.2%Jun+8.5%Jul+5.3%Aug+6.5%Sep−5.1%Oct+2.6%Nov+0.8%Dec

Over the last 10 years, the strongest month for WuXi Biologics (Cayman) has been July: +8.53% on average, positive in 7 years out of 10. The weakest has been October: −5.09% on average, positive in 4 years out of 10. November, the current month, has been positive in 4 years out of 9 (+2.56% on average).

Show chart data
MonthAverageMedianPositive years
January+5.31%+6.96%7 of 9
February+0.73%+1.21%5 of 9
March−0.20%+1.25%5 of 9
April−0.05%−3.92%4 of 9
May+0.25%+0.66%5 of 9
June+6.16%+3.59%6 of 9
July+8.53%+12.26%7 of 10
August+5.33%+0.86%6 of 10
September+6.55%+2.80%7 of 10
October−5.09%−6.52%4 of 10
November+2.56%−4.38%4 of 9
December+0.83%+0.90%5 of 9

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

WuXi Biologics (Cayman) and its competitors

The company is best known for platforms such as WuXiBody, SDArBodY, WuXiUP and WuXiHigh, which it applies across biologics work. Its activities run from early discovery and the preparation of investigational new drug filings through process development and commercial-scale production, and also include vaccine contract manufacturing, clinical and manufacturing services, and the development, production and distribution of biotechnological products. Operations are organised in two segments, Biologics and XDC, and the company serves customers in China, North America, Europe, Singapore, Japan, South Korea, Australia and Brazil.

Headquarters
Wuxi, China
Employees
14,705
Founded
2014
Chief executive
Zhisheng Chen
WuXi Biologics (Cayman) and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
WuXi Biologics (Cayman)2269$24.52B32.4%35.1+38.78%
Innovent Biologics1801$18.84B7.4%111.5+2.32%
Celltrion068270$36.68B31.6%26.4+19.29%
Sichuan Kelun-Biotech Biopharmaceutical6990$13.65B-0.2%—+0.78%
Sino Biopharmaceutical1177$12.49B28.2%36.7+2.23%
Samsung Biologics207940$49.13B45.5%33.4+0.28%

Same industry or related industries, similar size. Compare WuXi Biologics (Cayman) with its competitors · Full profile